179 related articles for article (PubMed ID: 37539023)
1. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
Lu X; Wang W
Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
[TBL] [Abstract][Full Text] [Related]
2. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
[TBL] [Abstract][Full Text] [Related]
3. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
Liu LC; Jin XH; Sun C; Xia JX
Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.
Albela H; Begum S; Leong KF
J Dermatolog Treat; 2022 May; 33(3):1769-1773. PubMed ID: 33706651
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
7. Combination of secukinumab and acitretin for generalized pustular psoriasis: A case report and review of literature.
Li J; Wang S; Li XD; Han Y
J Int Med Res; 2024 Apr; 52(4):3000605241247702. PubMed ID: 38661102
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: A case series of high efficacy and safety profile.
Polat Ekinci A; Bölük KN; Babuna Kobaner G
Dermatol Ther; 2021 Jan; 34(1):e14704. PubMed ID: 33368934
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.
Zhao Z; Zhang X; Wang R; Wang Y; Gong L; Li C
Dermatol Ther; 2022 Sep; 35(9):e15684. PubMed ID: 35789520
[TBL] [Abstract][Full Text] [Related]
11. Case report: Successful treatment of acute generalized pustular psoriasis of puerperium with secukinumab.
Xue G; Lili M; Yimiao F; Miao W; Xiaohong Y; Dongmei W
Front Med (Lausanne); 2022; 9():1072039. PubMed ID: 36569147
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis.
Miao C; Chen Y; Wang Z; Xiang X; Liu Y; Xu Z
J Dermatol; 2023 Feb; 50(2):258-261. PubMed ID: 35983654
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
Ho PH; Tsai TF
J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
[TBL] [Abstract][Full Text] [Related]
14. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
Pizzatti L; Mugheddu C; Sanna S; Atzori L; Rongioletti F
Dermatol Ther; 2020 May; 33(3):e13348. PubMed ID: 32239791
[TBL] [Abstract][Full Text] [Related]
15. Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study.
Damiani G; Pacifico A; Russo F; Pigatto PDM; Bragazzi NL; Bonifati C; Morrone A; Watad A; Adawi M
J Clin Med; 2019 May; 8(6):. PubMed ID: 31159169
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
[TBL] [Abstract][Full Text] [Related]
17. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab for the treatment of generalized pustular psoriasis: A case report.
Li J; Gao X; Ma L; Fang Y
Medicine (Baltimore); 2023 May; 102(18):e33693. PubMed ID: 37144985
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
20. Acitretin : A Review of its Pharmacology and Therapeutic Use.
Pilkington T; Brogden RN
Drugs; 1992 Apr; 43(4):597-627. PubMed ID: 28421560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
